Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
Most relevant news about MORPHOSYS AG
05/16MORPHOSYS AG : Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasi..
EQ
05/16MORPHOSYS AG : Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (M..
EQ
05/14MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/09MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/08MORPHOSYS AG : Reports First Quarter 2019 Results
AQ
05/07MORPHOSYS : Reports First Quarter 2019 Results
EQ
05/02MORPHOSYS : Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
PU
05/02MORPHOSYS : Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
EQ
05/02MORPHOSYS AG : quaterly earnings release
04/29MORPHOSYS : and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical..
PU
04/29MORPHOSYS : and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical..
EQ
04/23MORPHOSYS : and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106..
PU
04/23MORPHOSYS : and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106..
EQ
04/23MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
04/16MORPHOSYS AG : Notification and public disclosure of transactions by persons
EQ
More most relevant news
All news about MORPHOSYS AG
05/16MORPHOSYS AG : Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasi..
EQ
05/16MORPHOSYS AG : Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (M..
EQ
05/14MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/09MORPHOSYS AG : Release according to Article 40, Section 1 of the WpHG [the Germa..
EQ
05/08MORPHOSYS AG : Reports First Quarter 2019 Results
AQ
05/07MORPHOSYS : Reports First Quarter 2019 Results
EQ
05/02MORPHOSYS : Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
PU
05/02MORPHOSYS : Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
EQ
05/02MORPHOSYS AG : quaterly earnings release
04/29MORPHOSYS : and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical..
PU
More news
Sector news : Biotechnology & Medical Research - NEC
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
05/08GLOBAL MARKETS LIVE : Siemens, Airbus, Nestlé, Tesla…
More sector news : Biotechnology & Medical Research - NEC
Upcoming event on MORPHOSYS AG